Atrasentan in patients with IgA nephropathy (ALIGN): final 2.5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. (linkinghub.elsevier.com)

Authors: Heerspink HJL … Barratt J Journal: The Lancet Published: 2026-06-13 DOI: https://doi.org/10.1016/S0140-6736(26)00960-8